Current Science

Open Access Open Access  Restricted Access Subscription Access

Requirements for Biosimilar Authorization: A Legal and Comparative Perspective – FDA Versus EMA


Affiliations
1 Pharmacy Military Centre of Defence. Logistic Base San Pedro, Highway M-609 Miraflores, km 34, E-28770, Colmenar Viejo (Madrid), Spain
2 Universidad Complutense de Madrid, History of Pharmacy and Pharmaceutical Legislation, Department of Galenic Pharmacy and Food Technology. Ramon y Cajal Square s/n, E-28040, Madrid (Madrid), Spain
 

Both European Medicines Agency (EMA) and Food and Drug Administration (FDA) have developed a regulatory framework for the authorization of biosimilar medicines. Marketing authorization application must demonstrate that the biosimilar proposed has similar physicochemical, biological, clinical and non-clinical profiles to a reference biological medicine, which could be marketed upon expiration of the patent and data protection period of the innovative medicine. Although the basic principles to demonstrate biosimilarity are equivalent, there are significant differences in certain aspects. The biosimilarity criteria have not remained static, observing a reduction in the regulatory requirements established by EMA. On the other hand, several proposals concerning the amendment of biosimilarity demonstration have been suggested.

Keywords

Authorization, Biosimilar Medicines, Legal Perspective, Regulatory Framework.
User
Notifications
Font Size

  • EMA, Procedural advice for users of the centralised procedure for similar biological medicinal products applications, European Medicines Agency, EMA/940451/2011, 2012; https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-similar-biological-medicinal_en-0.pdf (accessed on 28 February 2020).

  • FDA, Biologics Price Competition and Innovation Act of 2009, Food and Drug Administration, 2009; https://www.govinfo.gov/content/pkg/FR-2010-12-08/pdf/2010-30713.pdf (accessed on 28 February 2020).

  • Kurki, P., van Aerts, L., Wolff-Holz, E., Giezen, T., Skibeli, V. and Weise, M., Interchangeability of biosimilars: a European perspective. BioDrugs, 2017, 31, 83–91.

  • Grampp, G. and Ramanan, S., The diversity of biosimilar design and development: implications for policies and stakeholders. BioDrugs, 2015, 29, 365–372.

  • de Mora, F., Biosimilar: what it is not. Br. J. Clin. Pharmacol., 2015, 80, 949–956.

  • Meher, B. R., Balan, S., Mohanty, R. R., Jena, M. and Das, S., Biosimilars in India; current status and future perspectives. J. Pharm. Bioallied Sci., 2019, 11, 12–15.

  • Saberwal, G., India to power the more widespread use for biosimilars? Curr. Sci., 2019, 116, 1451–1452.

  • EMA, Guideline on similar biological medicinal products, European Medicines Agency, CHMP/437/04 Rev 1, 23 October 2014; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf (accessed on 28 February 2020).

  • FDA, Biosimilar Development, Review, and Approval, Food and Drug Administration, 2019; http://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval (accessed on 28 February 2020).

  • Van de Vooren, K., Curto, A. and Garattini, L., Biosimilar versus generic drugs: same but different? Appl. Health Econ. Health Policy, 2015, 13, 125–127.

  • Duivelshof, B. L., Jiskoot, W., Beck, A., Veuthey, J.-L., Guillarme, D. and D’Atri, V., Glycosylation of biosimilars: recent advances in analytical characterization and clinical implications. Anal. Chim. Acta, 2019, 1089, 1–18.

  • Xiao, Z. et al., A comprehensive approach for evaluating charge heterogeneity in biosimilars. Eur. J. Pharm. Sci., 2018, 115, 19– 24.

  • Delgado Sánchez, O., Ginard Vicens, D., Sampol Mayol, A. and Terrasa Pons, J., Biosimilar medicines: impact, opportunities and strategies, Twelve years of experience in Europe. Med. Clín., 2019, 152, 411–415.

  • Girault, D. et al., Biosimilars: from technical to pharmacoeconomic considerations. Thérapie, 2015, 70, 47–55.

  • Dutta, A. S., Huys, I., Vulto, A. G., and Simoens, S., Identifying key benefits in European off‑patent biologics and biosimilars markets: it is not only about price! BioDrugs, 2019, 34, 203–211.

  • Cuellar, S., McBride, A. and Medina, P., Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. Am. J. Health Syst. Pharm., 2019, 76, 1725–1738.

  • Bellinvia, S., Cummings, J. R. F., Ardern-Jones, M. R. and Edwards, C. J., Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs, 2019, 33, 241–253.

  • Haustein, R., de Millas, C., Höer, A. and Häussler, B., Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat. J., 2012, 1, 120–126.

  • Kim, D., Transparency policies of the European medicines agency: has the paradigm shifted. Med. Law Rev., 2017, 25, 456–483.

  • Noguera Peña, A., La polémica en torno a la sustitución e intercambiabilidad de los medicamentos biosimilares en el ordenamiento jurídico español. Derecho Salud, 2019, 29, 5–52.

  • González, A. et al., La introducción de los biosimilares en España. Estimación del ahorro para el Sistema Nacional de Salud, Fundación Weber, Madrid, 2017.

  • Gascon, P., Krendyukov, A., Mathieson, N., Natek, M. and Aapro, M., Extrapolation in practice: lessons from 10 years with biosimilar filgrastim. BioDrugs, 2019, 33, 635–645.

  • Civoli, F. et al., Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. AAPS J., 2020, 22, 1–9.

  • Zúñiga Hernando, L. and Calvo Hernáez, B., Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol. Drug Saf., 2010, 19, 661–669.

  • Łukasik, Z. and Nowicki, M., Knowledge and attitude of community pharmacy employees towards an automatic drug substitution of generics and biosimilars. Acta Pol. Pharm., 2018, 75, 1247– 1254.

  • Tsiftsoglou, A. S., Ruiz, S. and Schneider, C. K., Development and regulation of biosimilars: current status and future challenges. BioDrugs, 2013, 27, 203–211.

  • McKinnon, R. A. et al., Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs, 2018, 32, 27– 52.

  • Haghnejad, V., Le Berre, C., Dominique, Y., Zallot, C., Guillemin, F. and Peyrin-Biroulet, L., Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Dig. Liver Dis., 2020, 52, 281–288.

  • Cohen, H. P., Blauvelt, A., Rifkin, R. M., Danese, S., Gokhale, S. B. and Woollett, G., Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs, 2018, 78, 463–478.

  • EMA, Guideline on similar biological medicinal products, European Medicines Agency, CHMP/437/04, 30 October 2005; https://www.ema.europa.eu/documents/scientific-guideline/guidelinesimilar-biological-medicinal-products-first-version_en.pdf (accessed on 28 February 2020).

  • FDA, Scientific considerations in demonstrating biosimilarity to a reference product, Food and Drug Administration, 2015; https://www.fda.gov/media/82647/download (accessed on 28 February 2020).

  • EMA, Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues, European Medicines Agency, EMEA/CHMP/BMWP/42832/2005 Rev. 1, 2014; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf (accessed on 28 February 2020).

  • FDA, Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations: guidance for industry, Food and Drug Administration, 2018; https://www.fda.gov/media/125484/download (accessed on 28 February 2020).

  • Jung, S. K. et al., Physicochemical characterization of Remsima®. mAbs, 2014, 6, 1163–1177.

  • Dent, M. and Matoba, N., Cancer biologics made in plants. Curr.Opin. Biotechnol., 2020, 61, 82–88.

  • Singh, A., Kalaivani, M., Srivastava, S., Goyal, R. K. and Gupta, S. K., Postmarketing safety of biosimilars: current status, challenges, and opportunities in the spontaneous reporting system. Ther. Innov. Regul. Sci., 2019.

  • Agbogbo, F. K. et al., Current perspectives on biosimilars. J. Ind. Microbiol. Biotechnol., 2019, 46, 1297–1311.

  • Vessely, C. and Bussineau, C., QbD in biopharmaceutical manufacturing and biosimilar development. In Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (eds Gutka, H., Yang, H. and Kakar, S.), Springer Healthcare, Cham, 2018, pp.187–220.

  • FDA, Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, Food and Drug Administration, 2016; https://www.fda.gov/media/88622/download (accessed on 28 February 2020).

  • Curigliano, G., O’Connor, D. P., Rosenberg, J. A. and Jacobs, I., Biosimilars: extrapolation for oncology. Crit. Rev. Oncol. Hematol., 2016, 104, 131–137.

  • Vezér, B., Buzás, Z., Sebeszta, M. and Zrubka, Z., Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.Curr. Med. Res. Opin., 2016, 32, 829–834.

  • Chamberlain, P. and Kurki, P., Immunogenicity assessment of biosimilars: a multidisciplinary perspective. In Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (eds Gutka, H., Yang, H. and Kakar, S.), Springer Healthcare, Cham, Switzerland, 2018, pp. 489–542.

  • Wolff-Holz, E., Tiitso, K., Vleminckx, C. and Weise, M., Evolution of the EU biosimilar framework: past and future. BioDrugs, 2019, 33, 621–634.

  • EMEA, Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (G-CSF), European Medicines Evaluation Agency, EMEA/CHMP/BMWP/31329/2005, 22 February 2006; https://www.ema.europa.eu/documents/scientific-guideline/annexguidelinesimilar-biological-medicinal-products-containing-biotechnologyderived-proteins_en.pdf (accessed on 28 February2020).

  • EMA, Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues, European Medicines Agency, EMA/CHMP/BMWP/32775/2005_Rev. 1, 26 February 2015; https://www.ema.europa.eu/documents/scientific-guideline/guidelinenonclinical-clinical-development-similar-biological-medicinalproductscontaining_en-0.pdf (accessed on 28 February 2020).

  • European Medicines Agency, Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins (EMEA/CHMP/BMWP/118264/2007 Rev. 1). 20 November 2016; https://www.ema.europa.eu/documents/scientific-guideline/guideline-non-clinicalclinicaldevelopment-similar-biological-medicinal-productscontaininglow_en.pdf (accessed on 28 February 2020).

  • Kovács, P. et al., Comparative physicochemical and biological characterization of the similar biological medicinal product teriparatide and its reference medicinal product. BioDrugs, 2020, 34, 65–75.

  • Genazzani, A. A. et al., Biosimilar drugs: concerns and opportunities.BioDrugs, 2007, 21, 351–356.

  • WHO, Biological Qualifier. An INN Proposal, World Health Organization, July 2014; http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf?ua=1 (accessed on 28 February 2020).

  • FDA, Nonproprietary naming of biological products guidance for industry, Food and Drug Administration, 2017; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm459987.pdf (accessed on 28 February 2020).

  • FDA, Considerations in demonstrating interchangeability with a reference product guidance for industry, Food and Drug Administration, 2019; https://www.fda.gov/media/124907/download (accessed on 28 February 2020).

  • Chance, K., FDA expectations for demonstrating interchangeability.Ther. Innov. Regul. Sci., 2018, 52, 369–373.

  • Vulto, A. G., Delivering on the promise of biosimilars. BioDrugs, 2019, 33, 599–602.

  • Cohen, H. P., Lamanna, W. C. and Schiestl, M., Totality of evidence and the role of clinical studies in establishing biosimilarity.In Biosimilars: Regulatory, Clinical and Biopharmaceutical Development (eds Gutka, H., Yang, H. and Kakar, S.), Springer Healthcare, Cham, Switzerland, 2018, pp. 601–628.

  • Velasco-Velázquez, Ma. et al., Extensive preclinical evaluation of an infliximab biosimilar candidate. Eur. J. Pharm. Sci., 2017, 102, 35–45.

  • EMEA, Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, Guideline on similar medicinal products containing somatropin, European Medicines Evaluation Agency. EMEA/CHMP/BMWP/94528/2005 Rev. 1, 28 June 2018; https://www.ema.europa.eu/documents/scientificguideline/annex-guideline-similar-biological-medicinal-productscontainingbiotechnology-derived-proteins_en-1.pdf (accessed on 28 February 2020).

  • EMA, Guideline on similar biological medicinal products containing interferon beta, European Medicines Agency, EMA/CHMP/BMWP/652000/2010, 21 February 2013; https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biologicalmedicinal-products-containing-interferon-beta_en.pdf (accessed on 28 February 2020).

  • EMA, Guideline on nonclinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision), European Medicines Agency, EMEA/CHMP/BMWP/301636/2008 Rev. 1, 23 July 2018; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinicalclinical-development-similar-biological-medicinal-productscontaining_ en-1.pdf (accessed on 28 February 2020).

  • EMA, Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH), European Medicines Agency, EMA/CHMP/BMWP/671292/2010), 21 February 2013; https://www.ema.europa.eu/documents/scientific-guideline/guidelinesimilar-biological-medicinal-products-containing-interferonbeta_ en.pdf (accessed on 28 February 2020).

  • EMA, Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues, European Medicines Agency, EMA/CHMP/BMWP/403543/2010, 30 May 2012; https://www.ema.europa.eu/en/documents/scientificguideline/guideline-similar-biological-medicinal-productscontainingmonoclonal-antibodies-non-clinical_en.pdf (accessed on 28 February 2020).

  • Frapaise, F.-X., The end of phase 3 clinical trials in biosimilars development? BioDrugs, 2018, 32, 319–324.

  • Ye, B. et al., Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet, 2019, 393, 1699–1707.

  • Jaworski, J. et al., Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res. Ther., 2019, 21.

  • Kim, Y. et al., Efficacy and safety of CKD-11101 (proposed biosimilar of darbepoetin-alfa) compared with darbepoetin-alfa in patients on hemodialysis: a randomized, double-blinded, parallelgroup phase III study. BioDrugs, 2020, 34, 99–110.

  • Clark, T., Jo, S. J. and Phillips, A., Sample size for biosimilar trials: in defense of synthesis. Ther. Innov. Regul. Sci., 2018, 52, 300–305.

  • Webster, C. J., Wong, A. C. and Woollett, G. R., An efficient development paradigm for biosimilars. BioDrugs, 2019, 33, 603– 611.


Abstract Views: 245

PDF Views: 80




  • Requirements for Biosimilar Authorization: A Legal and Comparative Perspective – FDA Versus EMA

Abstract Views: 245  |  PDF Views: 80

Authors

Alfonso Noguera Peña
Pharmacy Military Centre of Defence. Logistic Base San Pedro, Highway M-609 Miraflores, km 34, E-28770, Colmenar Viejo (Madrid), Spain
Carlos del Castillo Rodríguez
Universidad Complutense de Madrid, History of Pharmacy and Pharmaceutical Legislation, Department of Galenic Pharmacy and Food Technology. Ramon y Cajal Square s/n, E-28040, Madrid (Madrid), Spain

Abstract


Both European Medicines Agency (EMA) and Food and Drug Administration (FDA) have developed a regulatory framework for the authorization of biosimilar medicines. Marketing authorization application must demonstrate that the biosimilar proposed has similar physicochemical, biological, clinical and non-clinical profiles to a reference biological medicine, which could be marketed upon expiration of the patent and data protection period of the innovative medicine. Although the basic principles to demonstrate biosimilarity are equivalent, there are significant differences in certain aspects. The biosimilarity criteria have not remained static, observing a reduction in the regulatory requirements established by EMA. On the other hand, several proposals concerning the amendment of biosimilarity demonstration have been suggested.

Keywords


Authorization, Biosimilar Medicines, Legal Perspective, Regulatory Framework.

References





DOI: https://doi.org/10.18520/cs%2Fv120%2Fi1%2F56-65